These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9332764

  • 1. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
    Olson SH, Finstad CL, Harlap S, Kurian L, Saigo PE, Barakat RR.
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):815-7. PubMed ID: 9332764
    [Abstract] [Full Text] [Related]

  • 2. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study Group.
    J Natl Cancer Inst; 2005 Mar 02; 97(5):375-84. PubMed ID: 15741574
    [Abstract] [Full Text] [Related]

  • 3. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
    Otsuka I, Takahashi S, O'uchi K, Akimoto N, Hanari K, Ogaki Y, Enatsu YH, Takigawa A, Takaya H, Tanaka A, Kaseki H, Yamada T.
    Gan To Kagaku Ryoho; 2010 Feb 02; 37(2):279-83. PubMed ID: 20154485
    [Abstract] [Full Text] [Related]

  • 4. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M, Kodama T.
    In Vivo; 2001 Feb 02; 15(4):319-25. PubMed ID: 11695224
    [Abstract] [Full Text] [Related]

  • 5. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.
    Cancer Res; 2000 Apr 15; 60(8):2155-62. PubMed ID: 10786679
    [Abstract] [Full Text] [Related]

  • 6. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
    Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE, Comprehensive Cancer Centers TAMARISK-group.
    Breast Cancer Res Treat; 2008 Nov 15; 112(1):99-108. PubMed ID: 18064567
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.
    Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F.
    Cancer; 1998 May 01; 82(9):1698-703. PubMed ID: 9576291
    [Abstract] [Full Text] [Related]

  • 13. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.
    J Natl Cancer Inst; 2005 Nov 16; 97(22):1652-62. PubMed ID: 16288118
    [Abstract] [Full Text] [Related]

  • 14. Familial and nutritional risk factors for p53 overexpression in colorectal cancer.
    Freedman AN, Michalek AM, Marshall JR, Mettlin CJ, Petrelli NJ, Black JD, Zhang ZF, Satchidanand S, Asirwatham JE.
    Cancer Epidemiol Biomarkers Prev; 1996 Apr 16; 5(4):285-91. PubMed ID: 8722220
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
    Giordano G, Gnetti L, Merisio C, Melpignano M.
    Maturitas; 2007 Feb 20; 56(2):190-7. PubMed ID: 16963204
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.
    Clin Cancer Res; 2000 Jul 20; 6(7):2751-8. PubMed ID: 10914720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.